A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 25 Jul 2018 This trial was completed in Spain, according to European Clinical Trials Database.
- 30 Mar 2018 Planned End Date changed from 13 Jul 2018 to 16 Jul 2018.
- 30 Mar 2018 Planned primary completion date changed from 13 Jul 2018 to 16 Jul 2018.